Welcome to our dedicated page for Chimerix SEC filings (Ticker: CMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Chimerix, Inc. (NASDAQ: CMRX) provides access to the company’s regulatory disclosures as it advances medicines for patients facing deadly diseases, including rare brain cancers. Chimerix describes itself as a biopharmaceutical company whose most advanced clinical-stage program, dordaviprone (ONC201), is in development for H3 K27M-mutant diffuse glioma.
Although specific filings are not listed in the provided materials, investors typically look to Chimerix’s Forms 10-K and 10-Q for detailed information on its clinical programs, risk factors, research and development spending, and the status of regulatory submissions such as the New Drug Application for dordaviprone in recurrent H3 K27M-mutant diffuse glioma. Company press releases note that this NDA has been accepted by the U.S. Food and Drug Administration, granted Priority Review, and assigned a PDUFA target action date of August 18, 2025.
Filings are also the primary source for information about corporate transactions, including the definitive merger agreement under which Jazz Pharmaceuticals has agreed to acquire Chimerix for approximately $935 million in cash, or $8.55 per share, subject to customary closing conditions. Related tender offer documents and recommendation statements, when filed, would be accessible through the SEC’s EDGAR system and summarized on this page.
On Stock Titan, Chimerix filings are paired with AI-powered summaries that explain the key points of lengthy documents in plain language. As new quarterly reports, annual reports, and transaction-related filings become available from EDGAR, they are added in real time, allowing users to review Chimerix’s disclosed financial data, clinical program updates, and details of the announced acquisition by Jazz in a more digestible format.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they beneficially own 0.00 shares of Chimerix common stock, representing 0.0% of the class. The cover pages show 0.00 sole and shared voting power and 0.00 sole and shared dispositive power, indicating no reportable economic or voting stake in the issuer as disclosed.
The filing includes a joint filing agreement and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. It also states ownership is five percent or less and that the securities are held in the ordinary course of business and were not acquired to influence control.